- Cello's headline pre-tax profits rose by 8.0% to £4.6m in the six months to the end of June with continued rapid growth of Cello Health both organically and by acquisition.

Gross profit increased 12.9% to £49.1m (2016: £43.5m) on slightly lower revenue of £78.7m (2016: £80.8m).

Reported like-for-like gross profit growth was 5.4%. Headline operating profit was up 8.4% to £4.8m (2016: £4.4m).

The headline operating margin was 10.0% (2016: 10.3%).

Headline basic earnings per share were 3.43p (2016: 3.60p). Statutory earnings per share was 2.16p (2016: loss of 1.08p).

The group declared an interim dividend of 1.05p per share - up 5%.

Chief executive Mark Scott said: 'It has been an encouraging first half for the Group. Cello Health's strategy of focusing on expansion in the US is progressing well.

'The acquisition of Defined Health in February this year has already made a good contribution and we are very pleased with its integration in Cello Health which is also achieving strong organic growth, particularly in the US. Cello Signal is on track to meet expectations.

'The board is therefore confident of meeting market expectations for the year and is pleased to increase the interim dividend.'

Story provided by